Is Kiniksa Pharmaceuticals International PLC halal to invest in?

According to Musaffa's Shariah screening methodology, Kiniksa Pharmaceuticals International PLC (KNSA) is currently classified as HALAL as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Kiniksa Pharmaceuticals International PLC a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Kiniksa Pharmaceuticals International PLC using these criteria to determine its compliance status.

Can Muslims buy shares of Kiniksa Pharmaceuticals International PLC?

Muslim investors may consider investing in Kiniksa Pharmaceuticals International PLC if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Kiniksa Pharmaceuticals International PLC classified as HALAL?

Musaffa determines the Shariah status of Kiniksa Pharmaceuticals International PLC by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Kiniksa Pharmaceuticals International PLC updated?

The Shariah compliance status of Kiniksa Pharmaceuticals International PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Kiniksa Pharmaceuticals International PLC become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Kiniksa Pharmaceuticals International PLC?

You can check the latest Shariah compliance status of Kiniksa Pharmaceuticals International PLC on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

KNSA Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: May 01, 2026

Report Source: 2026 1st Quarter Report

Kiniksa Pharmaceuticals International PLC. Stock Analysis KNSA

United States Health Care Mid Cap Report: Q1, 2026

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.

Key Statistics of Kiniksa Pharmaceuticals International PLC (KNSA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$56.22$58.56

Today's Open

$58.00

Volume

471.52K

P/E Ratio (TTM)

73.72

52 Week Range

$24.85$59.87

Market Cap

4.37B

Avg. Volume

843.48K

Dividend Yield

Financial Metrics & Statements of Kiniksa Pharmaceuticals International PLC (KNSA)

FAQ's for Kiniksa Pharmaceuticals International PLC (KNSA)

According to Musaffa’s Shariah screening methodology, Kiniksa Pharmaceuticals International PLC (KNSA) is currently classified as HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.